Research Analysts Set Expectations for Innoviva Q3 Earnings

Key Points

• HC Wainwright has raised its Q3 2025 earnings per share estimate for Innoviva to $0.51, up from a previous forecast of $0.47, maintaining a "Buy" rating and a price target of $45.00.
• Innoviva recently reported quarterly earnings of $0.77 per share, exceeding analysts' expectations of $0.57, along with a revenue of $100.28 million compared to an estimated $87.10 million.
• Several brokerages have updated their ratings on Innoviva, with five analysts giving it a "Buy" rating and a consensus target price of $42.75.

Innoviva, Inc. (NASDAQ:INVA - Free Report) - Research analysts at HC Wainwright lifted their Q3 2025 earnings per share estimates for Innoviva in a report issued on Monday, August 11th. HC Wainwright analyst R. Selvaraju now expects that the biotechnology company will earn $0.51 per share for the quarter, up from their prior forecast of $0.47. HC Wainwright has a "Buy" rating and a $45.00 price target on the stock. The consensus estimate for Innoviva's current full-year earnings is $0.33 per share. HC Wainwright also issued estimates for Innoviva's Q4 2025 earnings at $0.54 EPS, Q1 2026 earnings at $0.57 EPS, Q3 2026 earnings at $0.73 EPS and FY2026 earnings at $2.77 EPS.

Innoviva (NASDAQ:INVA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.57 by $0.20. Innoviva had a return on equity of 18.67% and a net margin of 10.44%. The firm had revenue of $100.28 million during the quarter, compared to the consensus estimate of $87.10 million.

A number of other brokerages have also recently weighed in on INVA. Wall Street Zen upgraded Innoviva from a "hold" rating to a "buy" rating in a research note on Wednesday, April 30th. Oppenheimer began coverage on Innoviva in a research note on Monday. They issued an "outperform" rating and a $45.00 price objective for the company. Finally, Cantor Fitzgerald began coverage on Innoviva in a research note on Friday, July 11th. They issued an "overweight" rating and a $26.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $42.75.

Innoviva Price Performance

Shares of NASDAQ INVA opened at $20.09 on Wednesday. The company has a current ratio of 2.64, a quick ratio of 2.44 and a debt-to-equity ratio of 0.36. Innoviva has a twelve month low of $16.67 and a twelve month high of $22.00. The stock has a 50 day moving average of $19.85 and a two-hundred day moving average of $18.76. The stock has a market cap of $1.26 billion, a P/E ratio of 64.81 and a beta of 0.38.

Institutional Investors Weigh In On Innoviva

Several large investors have recently modified their holdings of INVA. Wells Fargo & Company MN raised its stake in shares of Innoviva by 40.3% during the fourth quarter. Wells Fargo & Company MN now owns 37,022 shares of the biotechnology company's stock worth $642,000 after purchasing an additional 10,637 shares during the last quarter. Sterling Capital Management LLC raised its stake in shares of Innoviva by 6.8% during the fourth quarter. Sterling Capital Management LLC now owns 22,924 shares of the biotechnology company's stock worth $398,000 after purchasing an additional 1,452 shares during the last quarter. Barclays PLC raised its stake in shares of Innoviva by 9.8% during the fourth quarter. Barclays PLC now owns 110,479 shares of the biotechnology company's stock worth $1,917,000 after purchasing an additional 9,885 shares during the last quarter. Marshall Wace LLP raised its stake in shares of Innoviva by 130.9% during the fourth quarter. Marshall Wace LLP now owns 314,968 shares of the biotechnology company's stock worth $5,465,000 after purchasing an additional 178,583 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co raised its position in Innoviva by 18.7% in the fourth quarter. CANADA LIFE ASSURANCE Co now owns 69,794 shares of the biotechnology company's stock worth $1,211,000 after acquiring an additional 10,993 shares in the last quarter. Hedge funds and other institutional investors own 99.12% of the company's stock.

About Innoviva

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.